Evaluating the Potential for Biomarker Use in CT Screening
Principal Investigator
Name
Hilary Robbins
Degrees
PhD MHS MSPH
Institution
International Agency for Research on Cancer (IARC)
Position Title
Scientist
Email
About this CDAS Project
Study
NLST
(Learn more about this study)
Project ID
NLST-476
Initial CDAS Request Approval
Jan 31, 2019
Title
Evaluating the Potential for Biomarker Use in CT Screening
Summary
At IARC, we are part of a large NCI-funded program (U19CA203654) evaluating the potential for genetic and blood-based biomarkers to improve multiple aspects of the lung cancer screening process. Specifically, we aim to assess whether one or more blood-based biomarkers could improve a) selection of ever-smokers into screening or b) management of nodules detected on CT.
We would like to analyze data from the NLST in various ways to help us understand whether use of biomarkers could improve the screening process. These include estimating individual risk during screening, modelling potential cost-effectiveness of incorporating biomarkers, and comparing NLST screening to other CT screening studies.
We would like to analyze data from the NLST in various ways to help us understand whether use of biomarkers could improve the screening process. These include estimating individual risk during screening, modelling potential cost-effectiveness of incorporating biomarkers, and comparing NLST screening to other CT screening studies.
Aims
1. Develop and validate risk models to calculate individual risk of lung cancer during screening;
2. Evaluate the potential cost-effectiveness of incorporating biomarker testing into the CT screening process;
3. Compare key aspects of the NLST screening process, such as screening benefits and screening harms (including overdiagnosis) to those from other CT screening studies.
Collaborators
Mattias Johansson, IARC
Paul Brennan, IARC
Tricia Larose, IARC
Florence Guida, IARC
Karine Alcala, IARC
Related Publications
-
The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials.
Li M, Zhang L, Charvat H, Callister ME, Sasieni P, Christodoulou E, Kaaks R, Johansson M, Carvalho AL, Vaccarella S, Robbins HA
Int J Cancer. 2022 Nov 1; Volume 151 (Issue 9): Pages 1491-1501 PUBMED -
Explaining differences in the frequency of lung cancer detection between the National Lung Screening Trial and community-based screening in Manchester, UK.
Robbins HA, Zahed H, Lebrett MB, Balata H, Johansson M, Sharman A, Evans DG, Crosbie EJ, Booton R, Landy R, Crosbie PAJ
Lung Cancer. 2022 Sep; Volume 171: Pages 61-64 PUBMED